Abstract:KRAS, a predominant member of the RAS family, is the most frequently mutated oncogene in human pancreatic cancer (∼95% of cases). Mutations in KRAS lead to its constitutive activation and activation of its downstream signaling pathways such as RAF/MEK/ERK and PI3K/AKT/mTOR that promote cell proliferation and provide apoptosis evasion capabilities to cancer cells. KRAS had been considered 'undruggable' until the discovery of the first covalent inhibitor targeting the G12C mutation. While G12C mutations are frequently found in non-small cell lung cancer, these are relatively rare in pancreatic cancer. On the other hand, pancreatic cancer harbors other KRAS mutations such as G12D and G12V. The inhibitors targeting G12D mutation (such as MRTX1133) have been recently developed, whereas those targeting other mutations are still lacking. Unfortunately, KRAS inhibitor monotherapy-associated resistance hinders their therapeutic efficacy. Therefore, various combination strategies have been tested and some yielded promising results, such as combinations with receptor tyrosine kinase, SHP2, or SOS1 inhibitors. In addition, we recently demonstrated that the combination of sotorasib with DT2216 (a BCL-XL-selective degrader) synergistically inhibits G12C-mutated pancreatic cancer cell growth in vitro and in vivo. This is in part because KRAS-targeted therapies induce cell cycle arrest and cellular senescence, which contributes to therapeutic resistance, while their combination with DT2216 can more effectively induce apoptosis. Similar combination strategies may also work for G12D inhibitors in pancreatic cancer. This chapter will review KRAS biochemistry, signaling pathways, different mutations, emerging KRAS-targeted therapies, and combination strategies. Finally, we discuss challenges associated with KRAS targeting and future directions, emphasizing pancreatic cancer.

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

KRAS mutation: from undruggable to druggable in cancer

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Targeting KRAS G12C Mutations in Colorectal Cancer.

Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Targeting KRAS-mutant Non-Small Cell Lung Cancer： Challenges and Opportunities

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Targeting KRAS in cancer

Drugging KRAS: current perspectives and state-of-art review

Targeting KRAS in Non-Small Cell Lung Cancer

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives

RAS‐targeted cancer therapy: Advances in drugging specific mutations

From bench to bedside: current development and emerging trend of KRAS-targeted therapy

KRAS: A Promising Therapeutic Target for Cancer Treatment

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Targeting KRAS: Crossroads of Signaling and Immune Inhibition

Multiple medicinal chemistry strategies of targeting KRAS: State-of-the art and future directions

Insights into Direct KRAS Inhibition Strategies for Cancer Treatment

Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers

Targeting KRASG12D Mutation in Non-Small Cell Lung Cancer: Molecular Mechanisms and Therapeutic Potential